UK markets close in 6 hours 32 minutes
  • FTSE 100

    7,464.85
    -48.59 (-0.65%)
     
  • FTSE 250

    19,966.45
    -179.73 (-0.89%)
     
  • AIM

    961.41
    -2.44 (-0.25%)
     
  • GBP/EUR

    1.1658
    -0.0110 (-0.93%)
     
  • GBP/USD

    1.2480
    -0.0108 (-0.86%)
     
  • BTC-GBP

    23,395.85
    -1,021.90 (-4.19%)
     
  • CMC Crypto 200

    652.46
    -22.42 (-3.32%)
     
  • S&P 500

    3,973.75
    +72.39 (+1.86%)
     
  • DOW

    31,880.24
    +618.34 (+1.98%)
     
  • CRUDE OIL

    110.08
    -0.21 (-0.19%)
     
  • GOLD FUTURES

    1,856.90
    +9.10 (+0.49%)
     
  • NIKKEI 225

    26,748.14
    -253.38 (-0.94%)
     
  • HANG SENG

    20,112.10
    -357.96 (-1.75%)
     
  • DAX

    14,030.45
    -144.95 (-1.02%)
     
  • CAC 40

    6,272.76
    -85.98 (-1.35%)
     

License partner of Xlife Sciences announces successful completion of phase 1 of in-vivo trial for ATROSIMAB – out-licensing of the compound intended

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Xlife Sciences AG / Key word(s): Annual Results

25-Apr-2022 / 07:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

Xlife Sciences AG (SIX: XLS) today announced that its project company Baliopharm has achieved an important R&D milestone in the development of the product candidate ATROSIMAB for the treatment of Non-alcoholic steatohepatitis (NASH) and potentially other chronic liver diseases. The phase 1 of the in-vivo trial evaluating the safety, tolerability and efficacy of ATROSIMAB has been successfully completed. Despite the challenges due to the Corona pandemic, Baliopharm was able to recruit all patients as planned. None of the patients experienced any serious side effects. Consequently, the compound can be classified as safe.

Oliver R. Baumann, CEO Xlife Sciences, comments: 'We congratulate Baliopharm's team for achieving this important milestone in the development of ATROSIMAB. Baliopharm will now evaluate the clinical trial in detail and subsequently intends to out-license the compound to a larger pharmaceutical partner. Moreover, we are pleased to announce that Baliopharm has already started conversations with selected players in the industry.'

Financial calendar

Annual Results 2021 April 29, 2022

Publication Valuation Report May 9, 2022

Ordinary General Assembly 2022 June 20, 2022

2022 Half-Year Results September 28, 2022

Contact

Information for journalists: IRF Reputation AG, Valentin Handschin, handschin@irf-reputation.ch

Information for investors: Xlife Sciences AG, Dennis Lennartz, dennis.lennartz@xlifesciences.ch

Xlife Sciences AG

Talacker 35

8001 Zürich

Telefon: 0041 44 385 84 60

E-Mail: info@xlifesciences.ch

Internet: www.xlifesciences.ch

ISIN: CH0461929603

WKN: A2PK6Z

Börsen: SIX Swiss Exchange

About Xlife Sciences AG (SIX: XLS)

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch

Disclaimer

Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.


End of ad hoc announcement

Language:

English

Company:

Xlife Sciences AG

Talacker 35

8001 Zürich

Switzerland

Phone:

+41 44 385 84 60

E-mail:

info@xlifesciences.ch

Internet:

www.xlifesciences.ch

ISIN:

CH0461929603

Valor:

A2PK6Z

Listed:

SIX Swiss Exchange

EQS News ID:

1333689


 

End of Announcement

EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting